Summary of Retigabine

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Trobalt 50 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 50 mg of retigabine. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
Film-coated tablet (tablet). 50 mg tablets: Purple, round, film-coated tablets, marked with RTG 50 on one side. 4. 4.1 CLINICAL PARTICULARS Therapeutic indications
Trobalt is indicated as adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and above with epilepsy. 4.2 Posology and method of administration
Posology Trobalt must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability. The maximum total daily starting dose is 300 mg (100 mg three times daily). Thereafter, the total daily dose is increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. An effective maintenance dose is expected to be between 600 mg/day and 1,200 mg/day. The maximum total maintenance dose is 1,200 mg/day. The safety and efficacy of doses higher than 1,200 mg/day have not been established. If patients miss one dose or more, it is recommended that they take a single dose as soon as they remember. After taking a missed dose, at least 3 hours should be allowed before the next dose and then the normal dosing schedule should be resumed. When withdrawing Trobalt, the dose must be gradually reduced (see section 4.4). Renal impairment Retigabine and its metabolites are eliminated principally by renal excretion. No dose adjustment is required in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min; see section 5.2).
A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe renal impairment (creatinine clearance <50 ml/min; see section 5.2). The total daily starting dose is 150 mg, and it is recommended that during the titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day. The effect of haemodialysis on retigabine clearance has not been adequately evaluated. Hepatic impairment No dose reduction is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6; see section 5.2). A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe hepatic impairment (Child-Pugh score 7; see section 5.2). The total daily starting dose is 150 mg, and it is recommended that during the titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day. Paediatric population The safety and efficacy of retigabine in children below 18 years of age have not been established yet. No data are available. Elderly (65 years of age and above) There are only limited data on the safety and efficacy of retigabine in patients aged 65 years and above. A reduction in the initial and maintenance dose of Trobalt is recommended in elderly patients. The total daily starting dose is 150 mg/day and during the titration period the total daily dose should be increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. Doses greater than 900 mg/day are not recommended (see sections 4.4 and 5.2). Method of administration Trobalt must be taken orally in three divided doses each day. It may be taken with or without food (see section 5.2). The tablets should be swallowed whole, and not chewed, crushed or divided. 4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients. 4.4 Special warnings and precautions for use
Urinary retention Urinary retention, dysuria and urinary hesitation were reported in controlled clinical studies with retigabine, generally within the first 8 weeks of treatment (see section 4.8). Trobalt must be used with caution in patients at risk of urinary retention, and it is recommended that patients are advised about the risk of these possible effects. QT interval A study of cardiac conduction in healthy subjects has demonstrated that retigabine titrated to 1,200 mg/day produced a QT-prolonging effect. A mean increase in Individual Corrected QT Interval (QTcI) of up to 6.7 ms (upper bound of 95% one-sided CI 12.6 ms) was observed within 3 hours of dosing. Caution should be taken when Trobalt is prescribed with medicinal products known to increase QT interval and in patients with known prolonged QT interval, congestive cardiac failure, ventricular hypertrophy, hypokalaemia or hypomagnesaemia and in patients initiating treatment who are 65 years of age and above. In these patients it is recommended that an electrocardiogram (ECG) is recorded before initiation of treatment with Trobalt and in those with a corrected QT interval >440ms at baseline, an ECG should be recorded on reaching the maintenance dose.
3
Psychiatric disorders Confusional state, psychotic disorders and hallucinations were reported in controlled clinical studies with retigabine (see section 4.8). These effects generally occurred within the first 8 weeks of treatment, and frequently led to treatment withdrawal in affected patients. It is recommended that patients are advised about the risk of these possible effects. Suicide risk Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo-controlled trials of antiepileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for Trobalt. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice if signs of suicidal ideation or behaviour emerge. Elderly (65 years of age and above) Elderly patients may be at increased risk of central nervous system events, urinary retention and atrial fibrillation. Trobalt must be used with caution in this population and a reduced initial and maintenance dose is recommended (see sections 4.2 and 5.2). Withdrawal seizures As with other antiepileptic drugs, Trobalt must be withdrawn gradually to minimise the potential for rebound seizures. It is recommended that the Trobalt dose is reduced over a period of at least 3 weeks, unless safety concerns require an abrupt withdrawal. 4.5 Interaction with other medicinal products and other forms of interaction
Interaction studies have only been performed in adults. Other antiepileptic drugs In vitro data indicated a low potential for interaction with other antiepileptic drugs (see section 5.2). The drug interaction potential was therefore evaluated based on a pooled analysis across clinical studies and whilst not considered as robust as stand-alone clinical interaction studies, the results support the in vitro data. Based on these pooled data, retigabine did not cause clinically significant effects on the plasma trough concentrations of the following antiepileptic drugs: carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, zonisamide. Further, based on pooled data, there were no clinically significant effects of the following antiepileptic drugs on retigabine pharmacokinetics: lamotrigine, levetiracetam, oxcarbazepine, topiramate, valproate. This analysis also showed no clinically significant effect of the inducers (phenytoin, carbamazepine and phenobarbital) on retigabine clearance. However, steady-state data from a limited number of patients in smaller phase II studies indicated that: phenytoin can reduce retigabine systemic exposure by 35% carbamazepine can reduce retigabine systemic exposure by 33%
Interaction with digoxin Data from an in vitro study showed that the N-acetyl metabolite of retigabine (NAMR) inhibited P-glycoprotein-mediated transport of digoxin in a concentration-dependent manner, indicating that NAMR may inhibit renal clearance of digoxin. Administration of Trobalt at therapeutic doses may increase digoxin serum concentrations. Interaction with anaesthetics Trobalt may increase the duration of anesthesia induced by some anaesthetics (for example thiopental sodium; see section 5.1). Interaction with alcohol Co-administration of ethanol (1.0 g/kg) with retigabine (200 mg) resulted in an increase in visual blurring in healthy volunteers. It is recommended that patients are advised about the possible effects on vision if they take Trobalt with alcohol. Laboratory tests Retigabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings. 4.6 Fertility, pregnancy and lactation
Pregnancy Risk related to antiepileptic drugs in general Specialist advice should be given to women who are of childbearing potential. The need for treatment with antiepileptic drugs should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of antiepileptic drug therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. The risk of congenital malformations is increased by a factor of 2 to 3 in the offspring of mothers treated with antiepileptic drugs compared with the expected incidence in the general population of approximately 3%. The most frequently reported defects are cleft lip, cardiovascular malformations and neural tube defects. Therapy with multiple antiepileptic drugs is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be used whenever possible. Risk related to Trobalt There are no adequate data from the use of retigabine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity because the plasma levels achieved in these studies were less than those reached in humans at recommended doses (see section 5.3). In a developmental study in rats whose mothers were treated with retigabine during pregnancy, there was a delay in auditory startle response development of the offspring (see section 5.3). The clinical significance of this finding is not known. Trobalt is not recommended during pregnancy and in women of childbearing age, not using contraception. Breastfeeding It is unknown whether retigabine is excreted in human breast milk. Animal studies have shown excretion of retagabine and/or its metabolites in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Trobalt should be made taking into account the benefit of breast-feeding to the child and the benefit of Trobalt therapy to the woman.
Fertility There were no treatment-related effects of retigabine on fertility in animal studies. However, the plasma levels achieved in these studies were less than those reached in humans at recommended doses (see section 5.3). The effect of retigabine on human fertility has not been established. 4.7 Effects on ability to drive and use machines
Adverse reactions such as dizziness, somnolence, diplopia and blurred vision were reported in controlled clinical studies, particularly during titration (see section 4.8). It is recommended that patients are advised about the risk of such adverse reactions at treatment initiation and following each titration step, and that they are advised not to drive or operate machinery until they have established how Trobalt affects them. As there is individual variation in response to all antiepileptic drug therapy, it is recommended that prescribers discuss with patients the specific issues of epilepsy and driving. 4.8 Undesirable effects
In pooled safety data from three multicentre, randomised, double-blind, placebo-controlled studies, adverse reactions were generally mild to moderate in intensity, and were most commonly reported in the first 8 weeks of treatment. There was an apparent dose-relationship for dizziness, somnolence, confusional state, aphasia, coordination abnormal, tremor, balance disorder, memory impairment, gait disturbance, blurred vision and constipation. Adverse reactions that were most frequently reported to lead to discontinuation were dizziness, somnolence, fatigue and confusional state. The following convention has been used for the classification of adverse reactions: Very common: Common: Uncommon: Rare: Very rare: 1/10 1/100 to <1/10 1/1,000 to <1/100 1/10,000 to <1/1,000 <1/10,000.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. System Organ Class Metabolism and nutrition disorders Psychiatric disorders Very common Common Weight increased Increased appetite Confusional state Psychotic disorders Hallucinations Disorientation Anxiety Dizziness Somnolence1 Amnesia1 Aphasia Coordination abnormal1 Vertigo1
6
Uncommon
Nervous system disorders
Hypokinesia
System Organ Class
Very common
Common Paraesthesia Tremor1 Balance disorder1 Memory impairment1 Dysphasia Dysarthria Disturbance in attention Gait disturbance1 Myoclonus
Uncommon
Eye disorders Gastrointestinal disorders
Diplopia Blurred vision Nausea Constipation Dyspepsia Dry mouth Increased liver function tests Skin rash Hyperhidrosis Dysuria Urinary hesitation Haematuria Chromaturia Fatigue Asthenia Malaise Peripheral oedema Urinary retention Nephrolithiasis Dysphagia
Hepatobiliary disorders Skin and subcutaneous disorders Renal and urinary disorders
General disorders and administrative site conditions

1
Data from elderly patients indicates that they may be more likely to experience certain central nervous system events.
Description of selected adverse reactions Adverse reactions related to voiding dysfunction, including urinary retention, were reported in 5% of retigabine-treated patients in the pooled safety dataset (see section 4.4). The majority of events occurred in the first 8 weeks of treatment, and there was no apparent dose-relationship. In retigabine-treated patients in the pooled dataset, confusional state was reported in 9% of patients, hallucinations in 2% of patients and psychotic disorders in 1% of patients (see section 4.4). The majority of adverse reactions occurred in the first 8 weeks of treatment, and there was an apparent dose-relationship for confusional state only. 4.9 Overdose
Symptoms and signs There is limited experience of overdose with retigabine.
Retigabine overdoses in excess of 2,500 mg/day were reported during clinical studies. In addition to adverse reactions seen at therapeutic doses, symptoms of retigabine overdose included agitation, aggressive behaviour and irritability. There were no reported sequelae. In a study in volunteers, cardiac arrhythmia (cardiac arrest/asystole or ventricular tachycardia) occurred in two subjects within 3 hours of receiving a single 900 mg retigabine dose. The arrhythmias spontaneously resolved, and both volunteers recovered without sequelae. Treatment In the event of overdose, it is recommended that the patient is given appropriate supportive therapy as clinically indicated, including electrocardiogram (ECG) monitoring. Further management should be as recommended by the national poisons centre, where available. 5. 5.1 PHARMACOLOGICAL PROPERTIES Pharmacodynamic properties
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX21. Mechanism of action Potassium channels are one of the voltage-gated ion channels found in neuronal cells and are important determinants of neuronal activity. In vitro studies indicate that retigabine acts primarily through opening neuronal potassium channels (KCNQ2 [Kv7.2] and KCNQ3 [Kv7.3]). This stabilises the resting membrane potential and controls the sub-threshold electrical excitability in neurons, thus preventing the initiation of epileptiform action potential bursts. Mutations in the KCNQ channels underlie several human inheritable disorders, including epilepsy (KCNQ2 and 3). The mechanism of action of retigabine on potassium channels has been well documented, however other mechanisms by which retigabine may assert an antiepileptic effect have yet to be fully elucidated. In a range of seizure models, retigabine increased the threshold for seizure induction produced by maximal electroshock, pentylenetetrazol, picrotoxin and N-methyl-D-aspartate (NMDA). Retigabine also displayed inhibitory properties in multiple kindling models, for example, in the fully kindled state and in some cases during the kindling development. In addition, retigabine was effective in preventing status epilepticus seizures in rodents with cobalt-induced epileptogenic lesions, and inhibiting tonic extensor seizures in genetically susceptible mice. The relevance of these models to human epilepsy, however, is not known. Pharmacodynamic effects In rats, retigabine increased the sleep time induced by thiopental sodium from approximately 4 min to 53 min, and the propofol-induced sleep time from approximately 8 min to 12 min. There was no effect on sleep time induced by halothane or methohexital sodium. Trobalt may increase the duration of anesthesia induced by some anaesthetics (for example thiopental sodium). Clinical efficacy of adjunctive retigabine therapy in partial onset seizures Three multicentre, randomized, double-blind, placebo-controlled studies in a total of 1239 adult patients have been conducted to assess the efficacy of retigabine as adjunctive therapy of partial onset seizures, with or without secondary generalisation. All patients enrolled were to have had seizures that were not adequately controlled with 1 to 3 concomitant antiepileptic drugs, and more than 75% of all patients were taking 2 concurrent antiepileptic drugs. Across all studies, patients had a mean duration of epilepsy of 22 years and a median baseline seizure frequency ranging from 8 to 12 per 28 days. Patients were randomized to placebo or retigabine at 600, 900 or 1,200 mg/day (see Table 1). During an 8-week baseline period, patients had to experience 4 partial onset seizures per 28 days. Patients could not be seizure-free for 21 days. The duration of the maintenance phase was 8 or 12 weeks.
The primary efficacy endpoints were: percentage change in the 28-day total partial seizure frequency from baseline to the double-blind phase (titration and maintenance phases combined) in all three studies responder rate (defined as the percentage of patients with a 50% reduction in 28-day total partial seizure frequency) from baseline to the maintenance phase (Studies 301 and 302 only). Retigabine was effective in adjunctive treatment of adults with partial onset seizures in three clinical studies (Table 1). Retigabine was statistically significantly superior to placebo at 600 mg/day (one study), 900 mg/day (two studies) and 1,200 mg/day (two studies). The studies were not designed to evaluate specific combinations of antiepileptic drugs. Consequently, the efficacy and safety of retigabine when taken concomitantly with antiepileptic drugs that were less commonly used as background treatment in the clinical studies, including levetiracetam, has not been definitely shown. Table 1. Summary of percentage changes in 28-day total partial seizure frequency and responder rates Study (n=population in double-blind phase; n=population in maintenance phase) Study 205 (n=396; n=303) Total partial seizure frequency (median) % change Responder rate (secondary endpoint) Study 301 (n=305; n=256) Total partial seizure frequency (median) % change Responder rate Study 302 (n=538; n=471) Total partial seizure frequency (median) % change Responder rate * ~ Statistically significant, p0.05 Dose not studied Placebo 600 mg/day -13% 26% -18% 23% -16% 19% -23% 28% ~ ~ -28%* 39%* Retigabine 900 mg/day -29%* 41% ~ ~ -40%* 47%*
1,200 mg/day -35%* 41%* -44%* 56%* ~ ~
In open-label extensions of the three placebo-controlled studies, persistence of efficacy was maintained over an evaluation period of at least 12 months (365 patients). Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies with retigabine in paediatric patients aged 0 to below 2 years with Lennox Gastaut Syndrome. The European Medicines Agency has deferred the obligation to submit the results of studies with retigabine in paediatric patients aged 2 to below 18 years with Lennox Gastaut Syndrome, and in paediatric patients aged 0 to below 18 years with partial onset seizures. 5.2 Pharmacokinetic properties
Absorption After both single and multiple oral doses, retigabine is rapidly absorbed with median tmax values generally between 0.5 and 2 hours. Absolute oral bioavailability of retigabine relative to an intravenous dose is approximately 60%.
Administration of retigabine with a high fat meal resulted in no change in the overall extent of retigabine absorption, but food reduced the between-subject variability in Cmax (23%) compared to the fasted state (41%), and led to an increase in Cmax (38%). The effect of food on Cmax under usual clinical conditions is not expected to be clinically relevant. Therefore Trobalt may be taken with or without food. Distribution Retigabine is approximately 80% bound to plasma protein over the concentration range of 0.1 to 2 g/ml. The steady state volume of distribution of retigabine is 2 to 3 l/kg following intravenous dosing. Biotransformation Retigabine is extensively metabolised in humans. A substantial fraction of the retigabine dose is converted to inactive N-glucuronides. Retigabine is also metabolised to an N-acetyl metabolite (NAMR) that is also subsequently glucuronidated. NAMR has antiepileptic activity, but is less potent than retigabine in animal seizure models. There is no evidence for hepatic oxidative metabolism of retigabine or NAMR by cytochrome P450 enzymes. Therefore co-administration with inhibitors or inducers of cytochrome P450 enzymes is unlikely to affect the pharmacokinetics of retigabine or NAMR. In vitro studies using human liver microsomes showed little or no potential for retigabine to inhibit the major cytochrome P450 isoenzymes (including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5). In addition, retigabine and NAMR did not induce CYP1A2 or CYP3A4/5 in human primary hepatocytes. Therefore retigabine is unlikely to affect the pharmacokinetics of substrates of the major cytochrome P450 isoenzymes through inhibition or induction mechanisms. Elimination Elimination of retigabine occurs via a combination of hepatic metabolism and renal excretion. A total of approximately 84% of the dose is recovered in the urine, including the N-acetyl metabolite (18%), N-glucuronides of the parent active substance and of the N-acetyl metabolite (24%), or parent active substance (36%). Only 14% of retigabine is excreted in the faeces. Retigabine has a plasma half-life of approximately 6 to 10 hours. The total clearance of retigabine from plasma following intravenous dosing is typically 0.4 to 0.6 l/h/kg. Linearity Retigabine pharmacokinetics are essentially linear over the single dose range of 25 to 600 mg in healthy volunteers and up to 1,200 mg daily in patients with epilepsy, with no unexpected accumulation following repeated administration. Special patient populations Renal impairment In a single dose study, retigabine AUC was increased by approximately 30% in volunteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and by approximately 100% in volunteers with moderate to severe renal impairment (creatinine clearance <50 ml/min), relative to healthy volunteers. Adjustment of the Trobalt dose is recommended in patients with moderate to severe renal impairment but no adjustment of the Trobalt dose is recommended in patients with mild renal impairment (see section 4.2). In a single dose study in volunteers with end stage renal disease, the retigabine AUC was increased by approximately 100% relative to healthy volunteers. However, the effect of haemodialysis on retigabine clearance was not adequately evaluated.
10
Hepatic impairment In a single dose study, there were no clinically significant effects on retigabine AUC in volunteers with mild hepatic impairment (Child-Pugh score 5 to 6). The retigabine AUC was increased by approximately 50% in volunteers with moderate hepatic impairment (Child-Pugh score 7 to 9) and by approximately 100% in volunteers with severe hepatic impairment (Child-Pugh score >9), relative to healthy volunteers. Adjustment of the Trobalt dose is recommended in patients with moderate or severe hepatic impairment (see section 4.2). Body weight In a population pharmacokinetic analysis, retigabine clearance increased with increasing body surface area. However, this increase is not considered to be clinically meaningful, and since retigabine is titrated according to individual patient response and tolerability, dose-adjustments are not required on the basis of body weight. Elderly (65 years of age and above) In a single-dose study, retigabine was eliminated more slowly by healthy elderly volunteers (66 to 82 years of age) relative to healthy young adult volunteers, resulting in a higher AUC (approximately 40 to 50%) and longer terminal half-life (30%) (see section 4.2). Gender The results of a single dose study showed that in young adult volunteers, retigabine Cmax was approximately 65% higher in females than in males, and in elderly volunteers (66 to 82 years of age), retigabine Cmax was approximately 75% higher in females compared with males. When Cmax was normalized for weight, the values were approximately 30% higher in young females than in males and 40% higher in elderly females compared with males. However, there was no apparent gender difference in weight-normalized clearance, and since retigabine is titrated according to individual patient response and tolerability, dose-adjustments are not required on the basis of gender. Race A post-hoc analysis across multiple healthy volunteer studies demonstrated a 20% reduction in retigabine clearance in healthy black volunteers relative to healthy Caucasian volunteers. However, this effect is not considered clinically significant, therefore no adjustment of the Trobalt dose is recommended. Paediatric population The pharmacokinetics of retigabine in children and adolescents have not been investigated. 5.3 Preclinical safety data
Maximum doses in repeat dose toxicity studies were limited by the exaggerated pharmacologic effects of retigabine (including ataxia, hypokinesia and tremor). At no observed effect levels, animal exposure in these studies was generally less than that reached in humans at recommended clinical doses. Distension of the gall bladder was seen in studies with dogs, but there was no evidence of cholestasis or other signs of gall bladder dysfunction, and bile ejection volume was unchanged. The gall bladder distension in the dog resulted in focal compression of the liver. No signs of gall bladder dysfunction were seen clinically. Preclinical data reveal no special hazard for humans based on studies of genotoxicity or carcinogenic potential. Reproductive toxicology Retigabine had no effect on fertility or general reproductive performance.
11
In rats, retigabine and/or its metabolites crossed the placenta resulting in tissue concentrations that were similar in dams and foetuses. There was no evidence of teratogenicity following administration of retigabine to pregnant animals during the period of organogenesis. In a study of peri- and post-natal development in rats, retigabine was associated with increased perinatal mortality following administration during pregnancy. In addition, there was a delay in auditory startle response development. These findings were apparent at exposure levels lower than those obtained with clinically recommended doses and were accompanied by maternal toxicities (including ataxia, hypokinesia, tremor and reduced body weight gain). The maternal toxicities interfered with higher dosing of the dams and hence deduction of safety margins with regard to human therapy. 6. 6.1 PHARMACEUTICAL PARTICULARS List of excipients
Tablet core Croscarmellose sodium Hypromellose Magnesium stearate Microcrystalline cellulose. Film-coating 50 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Indigo carmine aluminium lake (E132) Carmine (E120). Lecithin (SOY) Xanthan gum 6.2 Incompatibilities
Not applicable. 6.3 Shelf life
18 months. 6.4 Special precautions for storage
Do not store above 25C. 6.5 Nature and contents of container
50 mg tablets (maintenance packs): Opaque PVC-PVDC-aluminium foil blisters. Packs containing 21, 84 or 168 film-coated tablets. Not all pack sizes may be marketed.
12
6.6
Special precautions for disposal
No special requirements. 7. MARKETING AUTHORISATION HOLDER
Glaxo Group Limited Berkeley Avenue Greenford Middlesex UB6 0NN United Kingdom 8. MARKETING AUTHORISATION NUMBER(S)
EU/1/11/681/001, EU/1/11/681/002, EU/1/11/681/003
9.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28 March 2011 10. DATE OF REVISION OF THE TEXT
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
13
1.
Film-coated tablet (tablet). 100 mg tablets: Green, round, film-coated tablets, marked with RTG 100 on one side. 4. 4.1 CLINICAL PARTICULARS Therapeutic indications
Posology Trobalt must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability. The maximum total daily starting dose is 300 mg (100 mg three times daily). Thereafter, the total daily dose is increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. An effective maintenance dose is expected to be between 600 mg/day and 1,200 mg/day. The maximum total maintenance dose is 1,200 mg/day. The safety and efficacy of doses higher than 1,200 mg/day have not been established. If patients miss one dose or more, it is recommended that they take a single dose as soon as they remember. After taking a missed dose, at least 3 hours should be allowed before the next dose and then the normal dosing schedule should be resumed. When withdrawing Trobalt, the dose must be gradually reduced (see section 4.4). Renal impairment Retigabine and its metabolites are eliminated principally by renal excretion. No dose adjustment is required in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min; see section 5.2). A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe renal impairment (creatinine clearance <50 ml/min; see section 5.2). The total daily
14
starting dose is 150 mg, and it is recommended that during the titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day. The effect of haemodialysis on retigabine clearance has not been adequately evaluated. Hepatic impairment No dose reduction is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6; see section 5.2). A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe hepatic impairment (Child-Pugh score 7; see section 5.2). The total daily starting dose is 150 mg, and it is recommended that during the titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day. Paediatric population The safety and efficacy of retigabine in children below 18 years of age have not been established yet. No data are available. Elderly (65 years of age and above) There are only limited data on the safety and efficacy of retigabine in patients aged 65 years and above. A reduction in the initial and maintenance dose of Trobalt is recommended in elderly patients. The total daily starting dose is 150 mg/day and during the titration period the total daily dose should be increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. Doses greater than 900 mg/day are not recommended (see sections 4.4 and 5.2). Method of administration Trobalt must be taken orally in three divided doses each day. It may be taken with or without food (see section 5.2). The tablets should be swallowed whole, and not chewed, crushed or divided. 4.3 Contraindications
15
Interaction studies have only been performed in adults. Other antiepileptic drugs In vitro data indicated a low potential for interaction with other antiepileptic drugs (see section 5.2). The drug interaction potential was therefore evaluated based on a pooled analysis across clinical studies and whilst not considered as robust as stand-alone clinical interaction studies, the results support the in vitro data. Based on these pooled data, retigabine did not cause clinically significant effects on the plasma trough concentrations of the following antiepileptic drugs: carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, zonisamide. Further, based on pooled data, there were no clinically significant effects of the following antiepileptic drugs on retigabine pharmacokinetics: lamotrigine, levetiracetam, oxcarbazepine, topiramate, valproate. This analysis also showed no clinically significant effect of the inducers (phenytoin, carbamazepine and phenobarbital) on retigabine clearance. However, steady-state data from a limited number of patients in smaller phase II studies indicated that: phenytoin can reduce retigabine systemic exposure by 35% carbamazepine can reduce retigabine systemic exposure by 33% Interaction with digoxin Data from an in vitro study showed that the N-acetyl metabolite of retigabine (NAMR) inhibited P-glycoprotein-mediated transport of digoxin in a concentration-dependent manner, indicating that
16
NAMR may inhibit renal clearance of digoxin. Administration of Trobalt at therapeutic doses may increase digoxin serum concentrations. Interaction with anaesthetics Trobalt may increase the duration of anesthesia induced by some anaesthetics (for example thiopental sodium; see section 5.1). Interaction with alcohol Co-administration of ethanol (1.0 g/kg) with retigabine (200 mg) resulted in an increase in visual blurring in healthy volunteers. It is recommended that patients are advised about the possible effects on vision if they take Trobalt with alcohol. Laboratory tests Retigabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings. 4.6 Fertility, pregnancy and lactation
17
18
Uncommon
Hypokinesia
System Organ Class
Very common
Uncommon

1
19
20
1,200 mg/day -35%* 41%* -44%* 56%* ~ ~
21
22
23
Tablet core Croscarmellose sodium Hypromellose Magnesium stearate Microcrystalline cellulose. Film coating 100 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Indigo carmine aluminium lake (E132) Iron oxide yellow (E172). Lecithin (SOY) Xanthan gum 6.2 Incompatibilities
100 mg tablets (maintenance packs): Opaque PVC-PVDC-aluminium foil blisters. Packs containing 21, 84 or 168 film-coated tablets. Not all pack sizes may be marketed.
24
6.6
EU/1/11/681/004, EU/1/11/681/005, EU/1/11/681/006 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28 March 2011
10.
DATE OF REVISION OF THE TEXT
25
1.
Film-coated tablet (tablet). 200 mg tablets: Yellow, oblong, film-coated tablets, marked with RTG-200 on one side. 4. 4.1 CLINICAL PARTICULARS Therapeutic indications
26
27
28
29
30
Uncommon
Hypokinesia
System Organ Class
Very common
Uncommon

1
31
32
1,200 mg/day -35%* 41%* -44%* 56%* ~ ~
33
34
35
Tablet core Croscarmellose sodium Hypromellose Magnesium stearate Microcrystalline cellulose. Film-coating 200 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Iron oxide yellow (E172). Lecithin (SOY) Xanthan gum 6.2 Incompatibilities
200 mg tablets: Opaque PVC-PVDC-aluminium foil blisters. Pack containing 84 film-coated tablets; multi-pack comprising 168 (2 x 84) film-coated tablets. Not all pack sizes may be marketed.
36
6.6
EU/1/11/681/007, EU/1/11/681/008 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28 March 2011
10.
37
1.
Film-coated tablet (tablet). 300 mg tablets: Green, oblong, film-coated tablets, marked with RTG-300 on one side. 4. 4.1 CLINICAL PARTICULARS Therapeutic indications
38
39
Interaction studies have only been performed in adults. Other antiepileptic drugs In vitro data indicated a low potential for interaction with other antiepileptic drugs (see section 5.2). The drug interaction potential was therefore evaluated based on a pooled analysis across clinical studies and whilst not considered as robust as stand-alone clinical interaction studies, the results support the in vitro data. Based on these pooled data, retigabine did not cause clinically significant effects on the plasma trough concentrations of the following antiepileptic drugs: carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, zonisamide. Further, based on pooled data, there were no clinically significant effects of the following antiepileptic drugs on retigabine pharmacokinetics: lamotrigine, levetiracetam, oxcarbazepine, topiramate, valproate. This analysis also showed no clinically significant effect of the inducers (phenytoin, carbamazepine and phenobarbital) on retigabine clearance. However, steady-state data from a limited number of patients in smaller phase II studies indicated that: phenytoin can reduce retigabine systemic exposure by 35% carbamazepine can reduce retigabine systemic exposure by 33% Interaction with digoxin Data from an in vitro study showed that the N-acetyl metabolite of retigabine (NAMR) inhibited P-glycoprotein-mediated transport of digoxin in a concentration-dependent manner, indicating that
40
NAMR may inhibit renal clearance of digoxin. Administration of Trobalt at therapeutic doses may increase digoxin serum concentrations. Interaction with anaesthetics Trobalt may increase the duration of anesthesia induced by some anaesthetics (for example thiopental sodium; see section 5.1). Interaction with alcohol Co-administration of ethanol (1.0 g/kg) with retigabine (200 mg) resulted in an increase in visual blurring in healthy volunteers. It is recommended that patients are advised about the possible effects on vision if they take Trobalt with alcohol. Laboratory tests Retigabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings. 4.6 Fertility, pregnancy and lactation
41
42
Uncommon
Hypokinesia
System Organ Class
Very common
Uncommon

1
43
44
1,200 mg/day -35%* 41%* -44%* 56%* ~ ~
45
46
47
Tablet core Croscarmellose sodium Hypromellose Magnesium stearate Microcrystalline cellulose. Film-coating 300 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Indigo carmine aluminium lake (E132) Iron oxide yellow (E172). Lecithin (SOY) Xanthan gum 6.2 Incompatibilities
48
6.6
28 March 2011
10.
49
1.
Film-coated tablet (tablet). 400 mg tablets: Purple, oblong, film-coated tablets, marked with RTG-400 on one side. 4. 4.1 CLINICAL PARTICULARS Therapeutic indications
50
51
52
53
54
Uncommon
Hypokinesia
System Organ Class
Very common
Uncommon

1
55
56
1,200 mg/day -35%* 41%* -44%* 56%* ~ ~
57
58
59
Tablet core Croscarmellose sodium Hypromellose Magnesium stearate Microcrystalline cellulose. Film-coating 400 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Indigo carmine aluminium lake (E132) Carmine (E120). Lecithin (SOY) Xanthan gum 6.2 Incompatibilities
60
6.6
28 March 2011
10.
61
1.
Treatment initiation pack Trobalt 50 mg film-coated tablets Trobalt 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 50 mg of retigabine. Each film-coated tablet contains 100 mg of retigabine. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
Film-coated tablet (tablet). 50 mg tablets: Purple, round, film-coated tablets, marked with RTG 50 on one side. 100 mg tablets: Green, round, film-coated tablets, marked with RTG 100 on one side. 4. 4.1 CLINICAL PARTICULARS Therapeutic indications
Posology Trobalt must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability. The maximum total daily starting dose is 300 mg (100 mg three times daily). Thereafter, the total daily dose is increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. An effective maintenance dose is expected to be between 600 mg/day and 1,200 mg/day. The maximum total maintenance dose is 1,200 mg/day. The safety and efficacy of doses higher than 1,200 mg/day have not been established. If patients miss one dose or more, it is recommended that they take a single dose as soon as they remember. After taking a missed dose, at least 3 hours should be allowed before the next dose and then the normal dosing schedule should be resumed. When withdrawing Trobalt, the dose must be gradually reduced (see section 4.4).
62
Renal impairment Retigabine and its metabolites are eliminated principally by renal excretion. No dose adjustment is required in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min; see section 5.2). A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe renal impairment (creatinine clearance <50 ml/min; see section 5.2). The total daily starting dose is 150 mg, and it is recommended that during the titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day. The effect of haemodialysis on retigabine clearance has not been adequately evaluated. Hepatic impairment No dose reduction is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6; see section 5.2). A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe hepatic impairment (Child-Pugh score 7; see section 5.2). The total daily starting dose is 150 mg, and it is recommended that during the titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day. Paediatric population The safety and efficacy of retigabine in children below 18 years of age have not been established yet. No data are available. Elderly (65 years of age and above) There are only limited data on the safety and efficacy of retigabine in patients aged 65 years and above. A reduction in the initial and maintenance dose of Trobalt is recommended in elderly patients. The total daily starting dose is 150 mg/day and during the titration period the total daily dose should be increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. Doses greater than 900 mg/day are not recommended (see sections 4.4 and 5.2). Method of administration Trobalt must be taken orally in three divided doses each day. It may be taken with or without food (see section 5.2). The tablets should be swallowed whole, and not chewed, crushed or divided. 4.3 Contraindications
Urinary retention Urinary retention, dysuria and urinary hesitation were reported in controlled clinical studies with retigabine, generally within the first 8 weeks of treatment (see section 4.8). Trobalt must be used with caution in patients at risk of urinary retention, and it is recommended that patients are advised about the risk of these possible effects. QT interval A study of cardiac conduction in healthy subjects has demonstrated that retigabine titrated to 1,200 mg/day produced a QT-prolonging effect. A mean increase in Individual Corrected QT Interval (QTcI) of up to 6.7 ms (upper bound of 95% one-sided CI 12.6 ms) was observed within 3 hours of dosing. Caution should be taken when Trobalt is prescribed with medicinal products known to increase QT interval and in patients with known prolonged QT interval, congestive cardiac failure, ventricular
63
hypertrophy, hypokalaemia or hypomagnesaemia and in patients initiating treatment who are 65 years of age and above. In these patients it is recommended that an electrocardiogram (ECG) is recorded before initiation of treatment with Trobalt and in those with a corrected QT interval >440ms at baseline, an ECG should be recorded on reaching the maintenance dose. Psychiatric disorders Confusional state, psychotic disorders and hallucinations were reported in controlled clinical studies with retigabine (see section 4.8). These effects generally occurred within the first 8 weeks of treatment, and frequently led to treatment withdrawal in affected patients. It is recommended that patients are advised about the risk of these possible effects. Suicide risk Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo-controlled trials of antiepileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for Trobalt. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice if signs of suicidal ideation or behaviour emerge. Elderly (65 years of age and above) Elderly patients may be at increased risk of central nervous system events, urinary retention and atrial fibrillation. Trobalt must be used with caution in this population and a reduced initial and maintenance dose is recommended (see sections 4.2 and 5.2). Withdrawal seizures As with other antiepileptic drugs, Trobalt must be withdrawn gradually to minimise the potential for rebound seizures. It is recommended that the Trobalt dose is reduced over a period of at least 3 weeks, unless safety concerns require an abrupt withdrawal. 4.5 Interaction with other medicinal products and other forms of interaction
Interaction studies have only been performed in adults. Other antiepileptic drugs In vitro data indicated a low potential for interaction with other antiepileptic drugs (see section 5.2). The drug interaction potential was therefore evaluated based on a pooled analysis across clinical studies and whilst not considered as robust as stand-alone clinical interaction studies, the results support the in vitro data. Based on these pooled data, retigabine did not cause clinically significant effects on the plasma trough concentrations of the following antiepileptic drugs: carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, zonisamide. Further, based on pooled data, there were no clinically significant effects of the following antiepileptic drugs on retigabine pharmacokinetics: lamotrigine, levetiracetam, oxcarbazepine, topiramate, valproate. This analysis also showed no clinically significant effect of the inducers (phenytoin, carbamazepine and phenobarbital) on retigabine clearance. However, steady-state data from a limited number of patients in smaller phase II studies indicated that:
64
phenytoin can reduce retigabine systemic exposure by 35% carbamazepine can reduce retigabine systemic exposure by 33%
Pregnancy Risk related to antiepileptic drugs in general Specialist advice should be given to women who are of childbearing potential. The need for treatment with antiepileptic drugs should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of antiepileptic drug therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. The risk of congenital malformations is increased by a factor of 2 to 3 in the offspring of mothers treated with antiepileptic drugs compared with the expected incidence in the general population of approximately 3%. The most frequently reported defects are cleft lip, cardiovascular malformations and neural tube defects. Therapy with multiple antiepileptic drugs is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be used whenever possible. Risk related to Trobalt There are no adequate data from the use of retigabine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity because the plasma levels achieved in these studies were less than those reached in humans at recommended doses (see section 5.3). In a developmental study in rats whose mothers were treated with retigabine during pregnancy, there was a delay in auditory startle response development of the offspring (see section 5.3). The clinical significance of this finding is not known. Trobalt is not recommended during pregnancy and in women of childbearing age, not using contraception. Breastfeeding It is unknown whether retigabine is excreted in human breast milk. Animal studies have shown excretion of retagabine and/or its metabolites in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Trobalt should be made
65
taking into account the benefit of breast-feeding to the child and the benefit of Trobalt therapy to the woman. Fertility There were no treatment-related effects of retigabine on fertility in animal studies. However, the plasma levels achieved in these studies were less than those reached in humans at recommended doses (see section 5.3). The effect of retigabine on human fertility has not been established. 4.7 Effects on ability to drive and use machines
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. System Organ Class Metabolism and nutrition disorders Psychiatric disorders Very common Common Weight increased Increased appetite Confusional state Psychotic disorders Hallucinations Disorientation Anxiety Dizziness Somnolence1
66
Uncommon
Amnesia1 Aphasia
Hypokinesia
System Organ Class
Very common
Common Coordination abnormal1 Vertigo1 Paraesthesia Tremor1 Balance disorder1 Memory impairment1 Dysphasia Dysarthria Disturbance in attention Gait disturbance1 Myoclonus
Uncommon

1
Description of selected adverse reactions Adverse reactions related to voiding dysfunction, including urinary retention, were reported in 5% of retigabine-treated patients in the pooled safety dataset (see section 4.4). The majority of events occurred in the first 8 weeks of treatment, and there was no apparent dose-relationship. In retigabine-treated patients in the pooled dataset, confusional state was reported in 9% of patients, hallucinations in 2% of patients and psychotic disorders in 1% of patients (see section 4.4). The majority of adverse reactions occurred in the first 8 weeks of treatment, and there was an apparent dose-relationship for confusional state only.
67
4.9
Overdose
Symptoms and signs There is limited experience of overdose with retigabine. Retigabine overdoses in excess of 2,500 mg/day were reported during clinical studies. In addition to adverse reactions seen at therapeutic doses, symptoms of retigabine overdose included agitation, aggressive behaviour and irritability. There were no reported sequelae. In a study in volunteers, cardiac arrhythmia (cardiac arrest/asystole or ventricular tachycardia) occurred in two subjects within 3 hours of receiving a single 900 mg retigabine dose. The arrhythmias spontaneously resolved, and both volunteers recovered without sequelae. Treatment In the event of overdose, it is recommended that the patient is given appropriate supportive therapy as clinically indicated, including electrocardiogram (ECG) monitoring. Further management should be as recommended by the national poisons centre, where available. 5. 5.1 PHARMACOLOGICAL PROPERTIES Pharmacodynamic properties
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX21. Mechanism of action Potassium channels are one of the voltage-gated ion channels found in neuronal cells and are important determinants of neuronal activity. In vitro studies indicate that retigabine acts primarily through opening neuronal potassium channels (KCNQ2 [Kv7.2] and KCNQ3 [Kv7.3]). This stabilises the resting membrane potential and controls the sub-threshold electrical excitability in neurons, thus preventing the initiation of epileptiform action potential bursts. Mutations in the KCNQ channels underlie several human inheritable disorders, including epilepsy (KCNQ2 and 3). The mechanism of action of retigabine on potassium channels has been well documented, however other mechanisms by which retigabine may assert an antiepileptic effect have yet to be fully elucidated. In a range of seizure models, retigabine increased the threshold for seizure induction produced by maximal electroshock, pentylenetetrazol, picrotoxin and N-methyl-D-aspartate (NMDA). Retigabine also displayed inhibitory properties in multiple kindling models, for example, in the fully kindled state and in some cases during the kindling development. In addition, retigabine was effective in preventing status epilepticus seizures in rodents with cobalt-induced epileptogenic lesions, and inhibiting tonic extensor seizures in genetically susceptible mice. The relevance of these models to human epilepsy, however, is not known. Pharmacodynamic effects In rats, retigabine increased the sleep time induced by thiopental sodium from approximately 4 min to 53 min, and the propofol-induced sleep time from approximately 8 min to 12 min. There was no effect on sleep time induced by halothane or methohexital sodium. Trobalt may increase the duration of anesthesia induced by some anaesthetics (for example thiopental sodium). Clinical efficacy of adjunctive retigabine therapy in partial onset seizures Three multicentre, randomized, double-blind, placebo-controlled studies in a total of 1239 adult patients have been conducted to assess the efficacy of retigabine as adjunctive therapy of partial onset seizures, with or without secondary generalisation. All patients enrolled were to have had seizures that were not adequately controlled with 1 to 3 concomitant antiepileptic drugs, and more than 75% of all patients were taking 2 concurrent antiepileptic drugs. Across all studies, patients had a mean duration of epilepsy of 22 years and a median baseline seizure frequency ranging from 8 to 12 per 28 days. Patients were randomized to placebo or retigabine at 600, 900 or 1,200 mg/day (see Table 1). During
68
an 8-week baseline period, patients had to experience 4 partial onset seizures per 28 days. Patients could not be seizure-free for 21 days. The duration of the maintenance phase was 8 or 12 weeks. The primary efficacy endpoints were: percentage change in the 28-day total partial seizure frequency from baseline to the double-blind phase (titration and maintenance phases combined) in all three studies responder rate (defined as the percentage of patients with a 50% reduction in 28-day total partial seizure frequency) from baseline to the maintenance phase (Studies 301 and 302 only). Retigabine was effective in adjunctive treatment of adults with partial onset seizures in three clinical studies (Table 1). Retigabine was statistically significantly superior to placebo at 600 mg/day (one study), 900 mg/day (two studies) and 1,200 mg/day (two studies). The studies were not designed to evaluate specific combinations of antiepileptic drugs. Consequently, the efficacy and safety of retigabine when taken concomitantly with antiepileptic drugs that were less commonly used as background treatment in the clinical studies, including levetiracetam, has not been definitely shown. Table 1. Summary of percentage changes in 28-day total partial seizure frequency and responder rates Study (n=population in double-blind phase; n=population in maintenance phase) Study 205 (n=396; n=303) Total partial seizure frequency (median) % change Responder rate (secondary endpoint) Study 301 (n=305; n=256) Total partial seizure frequency (median) % change Responder rate Study 302 (n=538; n=471) Total partial seizure frequency (median) % change Responder rate * ~ Statistically significant, p0.05 Dose not studied Placebo 600 mg/day -13% 26% -18% 23% -16% 19% -23% 28% ~ ~ -28%* 39%* Retigabine 900 mg/day -29%* 41% ~ ~ -40%* 47%*
1,200 mg/day -35%* 41%* -44%* 56%* ~ ~
In open-label extensions of the three placebo-controlled studies, persistence of efficacy was maintained over an evaluation period of at least 12 months (365 patients). Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies with retigabine in paediatric patients aged 0 to below 2 years with Lennox Gastaut Syndrome. The European Medicines Agency has deferred the obligation to submit the results of studies with retigabine in paediatric patients aged 2 to below 18 years with Lennox Gastaut Syndrome, and in paediatric patients aged 0 to below 18 years with partial onset seizures.
69
5.2
Pharmacokinetic properties
Absorption After both single and multiple oral doses, retigabine is rapidly absorbed with median tmax values generally between 0.5 and 2 hours. Absolute oral bioavailability of retigabine relative to an intravenous dose is approximately 60%. Administration of retigabine with a high fat meal resulted in no change in the overall extent of retigabine absorption, but food reduced the between-subject variability in Cmax (23%) compared to the fasted state (41%), and led to an increase in Cmax (38%). The effect of food on Cmax under usual clinical conditions is not expected to be clinically relevant. Therefore Trobalt may be taken with or without food. Distribution Retigabine is approximately 80% bound to plasma protein over the concentration range of 0.1 to 2 g/ml. The steady state volume of distribution of retigabine is 2 to 3 l/kg following intravenous dosing. Biotransformation Retigabine is extensively metabolised in humans. A substantial fraction of the retigabine dose is converted to inactive N-glucuronides. Retigabine is also metabolised to an N-acetyl metabolite (NAMR) that is also subsequently glucuronidated. NAMR has antiepileptic activity, but is less potent than retigabine in animal seizure models. There is no evidence for hepatic oxidative metabolism of retigabine or NAMR by cytochrome P450 enzymes. Therefore co-administration with inhibitors or inducers of cytochrome P450 enzymes is unlikely to affect the pharmacokinetics of retigabine or NAMR. In vitro studies using human liver microsomes showed little or no potential for retigabine to inhibit the major cytochrome P450 isoenzymes (including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5). In addition, retigabine and NAMR did not induce CYP1A2 or CYP3A4/5 in human primary hepatocytes. Therefore retigabine is unlikely to affect the pharmacokinetics of substrates of the major cytochrome P450 isoenzymes through inhibition or induction mechanisms. Elimination Elimination of retigabine occurs via a combination of hepatic metabolism and renal excretion. A total of approximately 84% of the dose is recovered in the urine, including the N-acetyl metabolite (18%), N-glucuronides of the parent active substance and of the N-acetyl metabolite (24%), or parent active substance (36%). Only 14% of retigabine is excreted in the faeces. Retigabine has a plasma half-life of approximately 6 to 10 hours. The total clearance of retigabine from plasma following intravenous dosing is typically 0.4 to 0.6 l/h/kg. Linearity Retigabine pharmacokinetics are essentially linear over the single dose range of 25 to 600 mg in healthy volunteers and up to 1,200 mg daily in patients with epilepsy, with no unexpected accumulation following repeated administration. Special patient populations Renal impairment In a single dose study, retigabine AUC was increased by approximately 30% in volunteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and by approximately 100% in volunteers with moderate to severe renal impairment (creatinine clearance <50 ml/min), relative to healthy volunteers. Adjustment of the Trobalt dose is recommended in patients with moderate to severe renal
70
impairment but no adjustment of the Trobalt dose is recommended in patients with mild renal impairment (see section 4.2). In a single dose study in volunteers with end stage renal disease, the retigabine AUC was increased by approximately 100% relative to healthy volunteers. However, the effect of haemodialysis on retigabine clearance was not adequately evaluated. Hepatic impairment In a single dose study, there were no clinically significant effects on retigabine AUC in volunteers with mild hepatic impairment (Child-Pugh score 5 to 6). The retigabine AUC was increased by approximately 50% in volunteers with moderate hepatic impairment (Child-Pugh score 7 to 9) and by approximately 100% in volunteers with severe hepatic impairment (Child-Pugh score >9), relative to healthy volunteers. Adjustment of the Trobalt dose is recommended in patients with moderate or severe hepatic impairment (see section 4.2). Body weight In a population pharmacokinetic analysis, retigabine clearance increased with increasing body surface area. However, this increase is not considered to be clinically meaningful, and since retigabine is titrated according to individual patient response and tolerability, dose-adjustments are not required on the basis of body weight. Elderly (65 years of age and above) In a single-dose study, retigabine was eliminated more slowly by healthy elderly volunteers (66 to 82 years of age) relative to healthy young adult volunteers, resulting in a higher AUC (approximately 40 to 50%) and longer terminal half-life (30%) (see section 4.2). Gender The results of a single dose study showed that in young adult volunteers, retigabine Cmax was approximately 65% higher in females than in males, and in elderly volunteers (66 to 82 years of age), retigabine Cmax was approximately 75% higher in females compared with males. When Cmax was normalized for weight, the values were approximately 30% higher in young females than in males and 40% higher in elderly females compared with males. However, there was no apparent gender difference in weight-normalized clearance, and since retigabine is titrated according to individual patient response and tolerability, dose-adjustments are not required on the basis of gender. Race A post-hoc analysis across multiple healthy volunteer studies demonstrated a 20% reduction in retigabine clearance in healthy black volunteers relative to healthy Caucasian volunteers. However, this effect is not considered clinically significant, therefore no adjustment of the Trobalt dose is recommended. Paediatric population The pharmacokinetics of retigabine in children and adolescents have not been investigated. 5.3 Preclinical safety data
Maximum doses in repeat dose toxicity studies were limited by the exaggerated pharmacologic effects of retigabine (including ataxia, hypokinesia and tremor). At no observed effect levels, animal exposure in these studies was generally less than that reached in humans at recommended clinical doses. Distension of the gall bladder was seen in studies with dogs, but there was no evidence of cholestasis or other signs of gall bladder dysfunction, and bile ejection volume was unchanged. The gall bladder distension in the dog resulted in focal compression of the liver. No signs of gall bladder dysfunction were seen clinically.
71
Preclinical data reveal no special hazard for humans based on studies of genotoxicity or carcinogenic potential. Reproductive toxicology Retigabine had no effect on fertility or general reproductive performance. In rats, retigabine and/or its metabolites crossed the placenta resulting in tissue concentrations that were similar in dams and foetuses. There was no evidence of teratogenicity following administration of retigabine to pregnant animals during the period of organogenesis. In a study of peri- and post-natal development in rats, retigabine was associated with increased perinatal mortality following administration during pregnancy. In addition, there was a delay in auditory startle response development. These findings were apparent at exposure levels lower than those obtained with clinically recommended doses and were accompanied by maternal toxicities (including ataxia, hypokinesia, tremor and reduced body weight gain). The maternal toxicities interfered with higher dosing of the dams and hence deduction of safety margins with regard to human therapy. 6. 6.1 PHARMACEUTICAL PARTICULARS List of excipients
Tablet core Croscarmellose sodium Hypromellose Magnesium stearate Microcrystalline cellulose. Film-coating 50 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Indigo carmine aluminium lake (E132) Carmine (E120). Lecithin (SOY) Xanthan gum 100 mg tablets: Polyvinyl alcohol Titanium dioxide (E171) Talc (E553b) Indigo carmine aluminium lake (E132) Iron oxide yellow (E172). Lecithin (SOY) Xanthan gum 6.2 Incompatibilities
Not applicable.
72
6.3
Shelf life
Treatment initiation pack Opaque PVC-PVDC-aluminium foil blisters sealed into secondary heat-sealed card packaging. Pack containing 63 film-coated tablets (21 x 50 mg film-coated tablets and 42 x 100 mg film-coated tablets), presented as: one blister of 21 x 100 mg film-coated tablets one blister of 21 x 100 mg film-coated tablets and 21 x 50 mg film-coated tablets. Not all pack sizes may be marketed. 6.6 Special precautions for disposal
EU/1/11/681/013 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28 March 2011
10.
73
ANNEX II A. B. Manufacturing authorisation holder(s) responsible for batch release Conditions of the marketing authorisation
74
A.
Manufacturing authorisation holder(s) responsible for batch release
Name and address of the manufacturer(s) responsible for batch release Treatment Initiation Pack Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Estate Westhoughton Bolton, BL5 3XX United Kingdom All other packs Glaxo Wellcome S.A. Avda Extremadura 3 Aranda de Duero E-09400 Burgos Spain B.
Conditions of the marketing authorisation Conditions or restrictions regarding supply and use imposed on the marketing authorisation holder
Medicinal product subject to medical prescription.
Conditions or restrictions with regard to the safe and effective use of the medicinal product
Prior to launch in each Member State the MAH shall agree the final educational material with the National Competent Authority. The MAH shall ensure that, at launch, all physicians who are expected to prescribe TROBALT are provided with a physician information pack containing the following elements:

The Summary of Product Characteristics A physicians guide to prescribing including the following key messages: The need to inform patients that TROBALT may cause or potentiate symptoms of urinary retention/urinary hesitation The need to inform patients on adverse events related to QT interval prolongation Caution when using TROBALT in patients with a cardiac disease or those taking medicines concomitantly known to cause QT prolongation The need to inform patients to comply with dose titration to minimize the risk of hallucination and psychotic disorders Other conditions
75
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 4.0 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP. As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR). In addition, an updated RMP should be submitted
When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached At the request of the EMEA
76
ANNEX III LABELLING AND PACKAGE LEAFLET
77
A. LABELLING
78
PARTICULARS TO APPEAR ON THE OUTER PACKAGING HEAT-SEALED CARD PACK (2-WEEK TREATMENT INITIATION PACK)
1.
Trobalt 50 mg film-coated tablets Trobalt 100 mg film-coated tablets retigabine
2.
STATEMENT OF ACTIVE SUBSTANCE(S)
Each tablet contains 50 mg or 100 mg retigabine
3.
LIST OF EXCIPIENTS
4.
PHARMACEUTICAL FORM AND CONTENTS
Treatment initiation pack containing 63 film-coated tablets 50 mg 21 tablets 100 mg 42 tablets
5.
METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use Oral use Particulars to appear on the inner compartments of the heat sealed treatment initiation pack, which encloses the week 1 and week 2 blister foils.
79
half sun symbol Day 1 100 mg Day 2 100 mg Day 3 100 mg Day 4 100 mg Day 5 100 mg Day 6 100 mg Day 7 100 mg half sun symbol
sun symbol 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg sun symbol Week 1
moon symbol 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg moon symbol
half sun symbol Day 8 100 mg + 50 mg Day 9 100 mg + 50 mg Day 10 100 mg + 50 mg Day 11 100 mg + 50 mg Day 12 100 mg + 50 mg Day 13 100 mg + 50 mg Day 14 100 mg + 50 mg half sun symbol
sun symbol 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg sun symbol Week 2
moon symbol 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg 100 mg + 50 mg moon symbol
6.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
80
Keep out of the reach and sight of children
7.
OTHER SPECIAL WARNING(S), IF NECESSARY
8. EXP
EXPIRY DATE
9.
SPECIAL STORAGE CONDITIONS
Do not store above 25C
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Glaxo Group Limited Berkeley Avenue Greenford Middlesex UB6 0NN United Kingdom
12.
MARKETING AUTHORISATION NUMBER(S)
EU/1/11/681/013 13. Lot BATCH NUMBER
14.
GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription
15.
INSTRUCTIONS ON USE
16.
INFORMATION IN BRAILLE
trobalt 50 mg, 100 mg

81
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTERS (2-WEEK TREATMENT INITIATION PACK)
1.
Trobalt 50 mg 100 mg 2. NAME OF THE MARKETING AUTHORISATION HOLDER
3. EXP 4. Lot 5.
EXPIRY DATE
BATCH NUMBER
OTHER
82
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (MAINTENANCE PACKS)
1.
Trobalt 50 mg film-coated tablets retigabine
2.
Each tablet contains 50 mg retigabine
3.
LIST OF EXCIPIENTS
4.
21 tablets 84 tablets 168 tablets
5.
Read the package leaflet before use Oral use
6.
7.
8. EXP
EXPIRY DATE
9.
83
11.
12.
EU/1/11/681/001, EU/1/11/681/002, EU/1/11/681/003
13. Lot
BATCH NUMBER
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 50 mg
84
1.
2.
3.
LIST OF EXCIPIENTS
4.
21 tablets 84 tablets 168 tablets
5.
6.
7.
8. EXP
EXPIRY DATE
9.
85
11.
12.
EU/1/11/681/004, EU/1/11/681/005, EU/1/11/681/006
13. Lot
BATCH NUMBER
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 100 mg
86
1.
2.
3.
LIST OF EXCIPIENTS
4.
84 tablets
5.
6.
7.
8. EXP
EXPIRY DATE
9.
87
11.
12.
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 200 mg
88
1.
2.
3.
LIST OF EXCIPIENTS
4.
84 tablets
5.
6.
7.
8. EXP
EXPIRY DATE
9.
89
11.
12.
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 300 mg
90
1.
2.
3.
LIST OF EXCIPIENTS
4.
84 tablets
5.
6.
7.
8. EXP
EXPIRY DATE
9.
91
11.
12.
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 400 mg
92
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL (MAINTENANCE PACKS, WITH BLUE BOX MULTIPACK ONLY)
1.
2.
3.
LIST OF EXCIPIENTS
4.
168 tablets Multipack comprising 2 packs, each containing 84 film-coated tablets
5.
6.
7.
8.
EXPIRY DATE
9.
93
11.
Glaxo Group Limited
12.
EU/1/11/681/008 13. BATCH NUMBER
14.
15.
INSTRUCTIONS ON USE
16.
94
1.
2.
3.
LIST OF EXCIPIENTS
4.
5.
6.
7.
8.
EXPIRY DATE
9.
95
11.
Glaxo Group Limited
12.
14.
15.
INSTRUCTIONS ON USE
16.
96
1.
2.
3.
LIST OF EXCIPIENTS
4.
5.
6.
7.
8.
EXPIRY DATE
9.
97
11.
Glaxo Group Limited
12.
14.
15.
INSTRUCTIONS ON USE
16.
98
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON (MAINTENANCE PACKS WITHOUT BLUE BOX MULTIPACK ONLY)
1.
2.
3.
LIST OF EXCIPIENTS
4.
84 tablets Component of a multipack, not to be sold separately
5.
6.
7.
8. EXP
EXPIRY DATE
9.
99
11.
12.
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 200 mg
100
1.
2.
3.
LIST OF EXCIPIENTS
4.
5.
6.
7.
8. EXP
EXPIRY DATE
9.
101
11.
12.
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 300 mg
102
1.
2.
3.
LIST OF EXCIPIENTS
4.
5.
6.
7.
8. EXP
EXPIRY DATE
9.
103
11.
12.
14.
15.
INSTRUCTIONS ON USE
16.
trobalt 400 mg
104
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTERS (MAINTENANCE PACKS)
1.
Trobalt 50 mg tablets retigabine 2. NAME OF THE MARKETING AUTHORISATION HOLDER
Glaxo Group Limited 3. EXP 4. Lot 5. OTHER BATCH NUMBER EXPIRY DATE
105
1.
106
1.
107
1.
108
1.
109
B. PACKAGE LEAFLET
110
PACKAGE LEAFLET: INFORMATION FOR THE USER Trobalt 50 mg film-coated tablets Trobalt 100 mg film-coated tablets Trobalt 200 mg film-coated tablets Trobalt 300 mg film-coated tablets Trobalt 400 mg film-coated tablets Retigabine Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. 2. 3. 4. 5. 6. What Trobalt is and what it is used for Before you take Trobalt How to take Trobalt Possible side effects How to store Trobalt Further information
1.
What Trobalt is and what it is used for
Trobalt is one of a group of medicines called antiepileptics. It works by preventing the brain overactivity that causes epileptic seizures (also called fits). It is used with other medicines to treat adults who have a form of epilepsy, that affects one part of the brain, called partial onset seizures. These seizures may or may not be followed by a seizure affecting all of the brain (secondary generalisation). 2. Before you take Trobalt
Do not take Trobalt if you are allergic (hypersensitive) to retigabine or any of the other ingredients of Trobalt (listed in section 6). Tell your doctor if this applies to you, and dont take Trobalt. Take special care with Trobalt Before you take Trobalt your doctor needs to know: if you are 65 years of age or above. if you have kidney or liver problems. Tell your doctor if any of these applies to you. The doctor may decide to give you a reduced dose. Trobalt is not recommended for children aged under 18. The safety and effectiveness are not yet known in this age group.
111
Look out for serious symptoms Trobalt can cause serious side effects, including an inability to pass urine (urinary retention) and mental health problems. You must look out for certain symptoms while you are taking Trobalt, to reduce the risk of any problems. See 'Look out for serious symptoms' in section 4. Heart conditions Trobalt can affect heart rhythm. This is more likely to affect you: if you are taking other medicines if you have an existing heart problem if you have low potassium (hypokalaemia) or low magnesium (hypomagnesaemia) in your blood. if you are 65 years of age or above Tell your doctor if any of these apply to you, or if you notice any unusual changes in your heart beat (such as beating too fast or too slow). You may need extra check-ups (including an electrocardiogram [ECG], which is a test which records the electrical activity of your heart) while you are taking Trobalt. Thoughts of harming yourself or suicide A small number of people being treated with antiepileptics such as Trobalt have had thoughts of harming or killing themselves. If at any time you have these thoughts, Immediately contact your doctor. If you need a blood or urine test Trobalt can affect the results of some tests. If you need a blood or urine test: Tell the person who orders the test that you are taking Trobalt. Other medicines and Trobalt Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Trobalt may increase the level of digoxin (used to treat heart problems) in your blood. Tell your doctor if you are taking digoxin. Trobalt may affect some anaesthetics (for example thiopental sodium). If you are going to have an operation under a general anaesthetic: Tell the doctor that you are taking Trobalt, well in advance. Alcohol and Trobalt Drinking alcohol with Trobalt can make your vision blurred. Take extra care until you know how Trobalt and alcohol affect you. Pregnancy and breast-feeding You must only take Trobalt during pregnancy if your doctor tells you. There is no information about the safety of Trobalt in pregnant women. You must use a reliable method of contraception to avoid becoming pregnant while you are being treated with Trobalt. Talk to your doctor if you are pregnant, think you could be pregnant, or if you plan to become pregnant. Do not stop treatment without first discussing it with your doctor. It is not known whether the ingredients of Trobalt can pass into breast-milk. Talk to your doctor about breast-feeding while you are taking Trobalt. The doctor will weigh up the benefit to you against any risk to your baby of taking Trobalt while you are breast-feeding.
112
Driving and using machines Trobalt can make you feel dizzy or drowsy and cause double or blurred vision. Dont drive or use machines until you know how Trobalt affects you. You must talk to your doctor about the effect of your epilepsy on driving and using machines. 3. How to take Trobalt
Always take Trobalt exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure. How much to take The usual maximum starting dose of Trobalt is 100 mg, taken three times a day (a total of 300 mg a day). Your doctor may gradually adjust your dose over a few weeks so that your seizures are better controlled, and side effects are kept to a minimum. The maximum dose is 400 mg taken three times a day (a total of 1,200 mg a day). If you are over 65 years you will usually be given a reduced starting dose and your doctor may limit the maximum dose to 900 mg a day. If you have kidney or liver problems, your doctor may give you a reduced dose of Trobalt. Dont take any more Trobalt than your doctor has recommended. It may take a few weeks to find the right dose of Trobalt for you. How to use a Treatment Initiation Pack You may have been given a Treatment Initiation Pack to start your treatment with Trobalt. This pack contains all the Trobalt tablets you will need to take during your first two weeks of treatment. The tablets are contained in two blister wallets, marked week 1 and week 2. During your first week of treatment (days 1 to 7), you should take one 100 mg tablet three times a day. During the second week of treatment (days 8 to 14), you should take one 100 mg tablet and one 50 mg tablet together, three times a day. How to take Swallow the tablet whole. Dont chew, crush or split the tablet. You can take Trobalt with or without food. If you take more Trobalt than you should If you take too many tablets of Trobalt, you may be more likely to have side effects, or any of these symptoms: feeling agitated, aggressive or irritable effects on heart rhythm. Contact your doctor or pharmacist for advice if you ever take more Trobalt than you are prescribed. If possible, show them the medicine pack. If you forget to take Trobalt If you miss any doses, just take one dose as soon as you remember. Then leave at least 3 hours before your next dose. Don't take more than one dose at a time to make up for missed doses. If you are not sure what to do, ask your doctor or pharmacist.
113
Dont stop taking Trobalt without advice Take Trobalt for as long as your doctor recommends. Dont stop unless your doctor advises you to. If you suddenly stop taking Trobalt, your seizures may come back or get worse. Do not reduce your dose unless your doctor tells you to. To stop taking Trobalt, it is important that the dose is reduced gradually, over at least 3 weeks. 4. Possible side effects
Like all medicines, Trobalt can cause side effects, although not everybody gets them. Look out for serious symptoms Problems passing urine These are common in people taking Trobalt, and can lead to not being able to pass urine at all. This is most likely to happen during the first few months of treatment with Trobalt. Symptoms include: pain when passing urine (dysuria) difficulty in starting to urinate (urinary hesitation) not being able to pass urine (urinary retention). Tell your doctor immediately if you get any of these symptoms. Mental health problems These are common in people taking Trobalt, and are most likely to happen during the first few months of treatment. Symptoms include: confusion psychotic disorders (severe mental health problems) hallucinations (seeing or hearing things that are not there). Tell your doctor as soon as possible if you get any of these symptoms. Your doctor may decide that Trobalt is not suitable for you. Very common side effects These may affect more than 1 in 10 people: dizziness drowsiness lack of energy. If any of these effects gets serious, tell your doctor or pharmacist. Common side effects These may affect up to 1 in 10 people: blood in the urine; abnormally coloured urine feeling disorientated; anxiety memory problems (amnesia) difficulty in reading, writing or saying what you mean, or difficulty in understanding words attention problems lack of co-ordination; spinning sensation (vertigo); balance problems; problems walking tremors; sudden jerking of muscles (myoclonus) tingling or numbness of the hands or feet double or blurred vision constipation; feeling sick (nausea); indigestion; dry mouth weight gain; increased appetite swelling of lower legs and feet feeling weak or generally unwell changes in liver function, which will show up in blood tests. If any of these effects gets serious, tell your doctor or pharmacist.
114
Uncommon side effects These may affect up to 1 in 100 people: slow or reduced muscle movement difficulty in swallowing skin rash excessive sweating kidney stones. Elderly If you are 65 years or older, you may be more likely than a younger adult to get the following symptoms: drowsiness memory problems balance problems, lack of co-ordination, spinning sensation (vertigo), problems walking tremors If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 5. How to store Trobalt
Keep out of the reach and sight of children. Do not use Trobalt after the expiry date which is stated on the pack. The expiry date refers to the last day of that month. Do not store above 25C. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. 6. Further information
What Trobalt contains The active substance is retigabine. Each tablet contains 50 mg, 100 mg, 200 mg, 300 mg or 400 mg retigabine. The other ingredients are: croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, titanium dioxide (E171) , talc (E553b), Lecithin (SOY) and Xanthan gum. The 50 mg and 400 mg tablets also contain indigo carmine aluminium lake (E132) and carmine (E120). The 100 mg and 300 mg tablets also contain indigo carmine aluminium lake (E132) and iron oxide yellow (E172). The 200 mg tablets also contain iron oxide yellow (E172). What Trobalt looks like and contents of the pack Trobalt 50 mg tablets are purple, round and marked RTG 50 on one side. Each pack contains blisters of 21, 84 or 168 film-coated tablets. Trobalt 100 mg tablets are green, round and marked RTG 100 on one side. Each pack contains blisters of 21, 84 or 168 film-coated tablets. Trobalt 200 mg tablets are yellow, oblong and marked RTG-200 on one side. Each pack contains
115
blisters of 84 or 2 x 84 film-coated tablets. Trobalt 300 mg tablets are green, oblong and marked RTG-300 on one side. Each pack contains blisters of 84 or 2 x 84 film-coated tablets. Trobalt 400 mg tablets are purple, oblong and marked RTG-400 on one side. Each pack contains blisters of 84 or 2 x 84 film-coated tablets. A Treatment Initiation Pack is also available for use during the first two weeks of treatment when the dose is being slowly increased. The Treatment Initiation Pack contains 63 tablets, in 2 blisters. The blister for Week 1 of treatment contains 21 x 100 mg tablets. The blister for Week 2 contains 21 x 50 mg tablets and 21 x 100 mg tablets. Not all pack sizes may be available in your country. Marketing Authorisation Holder Glaxo Group Limited, Berkeley Avenue, Greenford, Middlesex UB6 0NN, United Kingdom. Manufacturer Treatment Initiation Pack Catalent UK Packaging Limited, Lancaster Way, Wingates Industrial Estate, Westhoughton, Bolton BL5 3XX, United Kingdom. All other packs Glaxo Wellcome, S.A, Avda. Extremadura 3, 09400 Aranda De Duero, Burgos, Spain. For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi/Belgique/Belgien GlaxoSmithKline s.a./n.v. Tl/Tel: + 32 (0)2 656 21 11 Te.: + 359 2 953 10 34 esk republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 [email protected] Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 [email protected] Deutschland GlaxoSmithKline GmbH & Co. KG Tel.: + 49 (0)89 36044 8701 [email protected] Eesti GlaxoSmithKline Eesti O Tel: + 372 6676 900 [email protected]
116
Luxembourg/Luxemburg GlaxoSmithKline s.a./n.v. Belgique/Belgien Tl/Tel: + 32 (0)2 656 21 11 Magyarorszg GlaxoSmithKline Kft. Tel.: + 36 1 225 5300 Malta GlaxoSmithKline Malta Tel: + 356 21 238131 Nederland GlaxoSmithKline BV Tel: + 31 (0)30 6938100 [email protected] Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 [email protected] sterreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 [email protected]
GlaxoSmithKline A.E.B.E. : + 30 210 68 82 100 Espaa GlaxoSmithKline, S.A. Tel: + 34 902 202 700 [email protected] France Laboratoire GlaxoSmithKline Tl.: + 33 (0)1 39 17 84 44 [email protected] Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 sland GlaxoSmithKline ehf. Smi: + 354 530 3700 Italia GlaxoSmithKline S.p.A. Tel: + 39 (0)45 9218 111 GlaxoSmithKline (Cyprus) Ltd : + 357 22 39 70 00 Latvija GlaxoSmithKline Latvia SIA Tel: + 371 67312687 [email protected] Lietuva GlaxoSmithKline Lietuva UAB Tel: + 370 5 264 90 00 [email protected]
Polska GSK Commercial Sp. z o.o. Tel.: + 48 (0)22 576 9000 Portugal GlaxoSmithKline Produtos Farmacuticos, Lda. Tel: + 351 21 412 95 00 [email protected] Romnia GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208 Slovenija GlaxoSmithKline d.o.o. Tel: + 386 (0)1 280 25 00 [email protected] Slovensk republika GlaxoSmithKline Slovakia s. r. o. Tel: + 421 (0)2 48 26 11 11 [email protected] Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 [email protected] Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 [email protected] United Kingdom GlaxoSmithKline UK Tel: + 44 (0)800 221441 [email protected]
This leaflet was last approved in Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
117

Summary of Retigabine

Uploaded by

Copyright:

Available Formats

Summary of Retigabine

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Summary of Retigabine

Uploaded by

Copyright:

Available Formats

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

NAME OF THE MEDICINAL PRODUCT

Trobalt 50 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Nervous system disorders

System Organ Class

Eye disorders Gastrointestinal disorders

General disorders and administrative site conditions

Symptoms and signs There is limited experience of overdose with retigabine.

1,200 mg/day -35%* 41%* -44%* 56%* ~ ~

Not applicable. 6.3 Shelf life

18 months. 6.4 Special precautions for storage

Do not store above 25C. 6.5 Nature and contents of container

Special precautions for disposal

No special requirements. 7. MARKETING AUTHORISATION HOLDER

EU/1/11/681/001, EU/1/11/681/002, EU/1/11/681/003

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

28 March 2011 10. DATE OF REVISION OF THE TEXT

NAME OF THE MEDICINAL PRODUCT

Trobalt 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Nervous system disorders

System Organ Class

Eye disorders Gastrointestinal disorders

General disorders and administrative site conditions

Symptoms and signs There is limited experience of overdose with retigabine.

1,200 mg/day -35%* 41%* -44%* 56%* ~ ~

Not applicable. 6.3 Shelf life

18 months. 6.4 Special precautions for storage

Do not store above 25C. 6.5 Nature and contents of container

Special precautions for disposal

No special requirements. 7. MARKETING AUTHORISATION HOLDER

EU/1/11/681/004, EU/1/11/681/005, EU/1/11/681/006 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

DATE OF REVISION OF THE TEXT

NAME OF THE MEDICINAL PRODUCT

Trobalt 200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Nervous system disorders

System Organ Class

Eye disorders Gastrointestinal disorders

General disorders and administrative site conditions

Symptoms and signs There is limited experience of overdose with retigabine.

1,200 mg/day -35%* 41%* -44%* 56%* ~ ~

Not applicable. 6.3 Shelf life

18 months. 6.4 Special precautions for storage

Do not store above 25C. 6.5 Nature and contents of container

Special precautions for disposal

No special requirements. 7. MARKETING AUTHORISATION HOLDER

EU/1/11/681/007, EU/1/11/681/008 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

DATE OF REVISION OF THE TEXT

NAME OF THE MEDICINAL PRODUCT

Trobalt 300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Nervous system disorders

System Organ Class

Eye disorders Gastrointestinal disorders

General disorders and administrative site conditions

Symptoms and signs There is limited experience of overdose with retigabine.

1,200 mg/day -35%* 41%* -44%* 56%* ~ ~

Not applicable. 6.3 Shelf life

18 months. 6.4 Special precautions for storage

Do not store above 25C. 6.5 Nature and contents of container

Special precautions for disposal